RESAPP HEALTH LIMITE

RAP
End-of-day quote. End-of-day quote  - 10/27
0.105AUD -4.55%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: June 2020 2021
Net sales1 -7,50
EBITDA1 -8,360,28
Operating profit (EBIT) --
Operating Margin --
Pre-Tax Profit (EBT)1 -8,470,10
Net income1 -8,470,10
Net margin -1,33%
EPS2 -0,01-
Dividend per Share2 --
Last update 08/31/202009/01/2020
1 AUD in Million
2 AUD
Estimates
Finances - Leverage
Fiscal Period: June 2020 2021
Net Debt1 --
Net Cash position1 5,457,71
Leverage (Debt / EBITDA) 0,65x-27,7x
Free Cash Flow --
ROE (Net Profit / Equities) -115%1,65%
Shareholders' equity1 7,346,05
ROA (Net Profit / Asset) -92,7%0,44%
Assets1 9,1322,7
Book Value Per Share2 0,010,01
Cash Flow per Share2 -0,010,00
Capex --
Capex / Sales --
Last update 08/31/202009/01/2020
1 AUD in Million
2 AUD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 80 M AUD -
Entreprise Value (EV) 71,9 M AUD 63,9 M AUD
Valuation 2021e 2022e
P/E ratio (Price / EPS) - 11,7x
Capitalization / Revenue 10,6x 5,31x
EV / Revenue 9,59x 4,79x
EV / EBITDA 258x 9,52x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 10,1x 5,07x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 0 0
Operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) 1,33% 49,3%
ROA (Net Profit / Asset) 0,44% 47,5%
ROE (Net Profit / Equities) 1,65% 60,3%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   0 0
Cash Flow / Sales 11,8% 44,9%
Capital Intensity (Assets / Sales) 3,02x 1,04x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend